Jun 14, 2023 / 05:40PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. Welcome, everyone. We'll continue with the next session. My name is Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome the management team from PTC. To my immediate right, we have Dr. Matt Klein. And at the far end there, we have Kylie O'Keefe.
What we'll do is the usual format. Maybe I'll let Matt kick it off with a couple of high-level comments, and then we'll go into Q&A. If anybody in the audience has questions along the way, please feel free to raise your hand, and we'll get a mic to you. Also, for those who are listening on the webcast, if you have any questions, please e-mail them to us, and we'll read them anonymously if time allows.
But otherwise, with that, I'll let Matt kick it off here.
Matthew B. Klein - PTC Therapeutics, Inc. - CEO & Director
Great. Thanks so much, Paul. It's great to be here today. For those of you who don't know PTC, we are a global biopharmaceutical company
PTC Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers